Quick Take
- KKR is buying Medicover India for EUR 1.2 Bn ($1.39 Bn, about Rs 13,190 Cr), an all-cash acquisition.
- Medicover India runs 24 hospitals and 4,800 beds across South and West India, with 1,900 doctors.
- This is KKR’s third India hospital bet in two years, after Baby Memorial and HCG in 2024 and 2025.
In This Article
Global investment firm KKR has signed definitive agreements to buy Medicover India, and the KKR Medicover India Deal values the hospital chain at EUR 1.2 Bn ($1.39 Bn, roughly Rs 13,190 Cr). Medicover AB announced the sale on August 6, 2026.
The buyer is acquiring the full India hospital operations of Sweden-listed Medicover AB (Nasdaq Stockholm: MCOV B). The seller said the divestment lets it refocus on Poland, Germany, and Romania, and it expects to close the deal in the fourth quarter of 2026, according to its official announcement carried on Business Wire. USD to INR is converted at Rs 109.9 per dollar equivalent, the spot rate on August 5, 2026 (BookMyForex).
StartupFeed Insight
The math tells the real story: Medicover India earns EUR 26.1 Mn EBITDA on EUR 220.5 Mn revenue, so KKR is paying close to 46 times EBITDA. That number only works if you believe India’s high-acuity hospital demand keeps compounding, which is exactly the thesis KKR has ridden through Max Healthcare, HCG, and Baby Memorial. Watch mid-tier regional chains next: this price sets a fresh benchmark, and three or four more South and West India hospital groups will likely field private-equity offers before March 2027. Founders in health-tech adjacent to hospital delivery should track this closely. By Soumya Verma.
KKR Medicover India Deal: The Breakdown
The KKR Medicover India Deal is an all-cash purchase of 100% of Medicover India, the country’s hospital arm of Medicover AB. Medicover AB holds 66.1% of the India unit directly, with minority shareholders owning the remaining 33.9%, per the Medicover AB disclosure.
| Metric | Detail | Notes |
|---|---|---|
| Deal Value | EUR 1.2 Bn ($1.39 Bn, Rs 13,190 Cr) | All-cash, 100% acquisition |
| Buyer | KKR (NYSE: KKR) | Funds managed by KKR |
| Seller | Medicover AB (Nasdaq Stockholm: MCOV B) | Held 66.1% of the India unit |
| Seller Proceeds | EUR 740 Mn gross cash | Per Medicover AB, to cut debt and refocus on Europe |
| Target Revenue (LTM) | EUR 220.5 Mn (about Rs 2,423 Cr) | Trailing 12 months to June 30, 2026 |
| Announcement Date | August 6, 2026 | Expected close: Q4 2026 |
The most striking figure is the seller’s net: EUR 740 Mn in gross cash proceeds against a EUR 1.2 Bn headline, reflecting the 33.9% minority stake and net debt inside the India unit, per the Medicover AB statement.
About Medicover India
Medicover India is a multi-specialty hospital network founded in 2017 under Swedish parent Medicover AB. Headquartered in Hyderabad, it runs 24 hospitals with about 4,800 beds across South and West India, offering care in more than 80 clinical specialties. It is supported by more than 1,900 doctors and around 11,400 employees, and generated EUR 220.5 Mn in revenue for the 12 months to June 30, 2026, per Medicover AB.
Why did KKR back Medicover India?
KKR backed Medicover India because it fits the firm’s long-running thesis on India’s high-acuity hospital demand. Cardiology, oncology, and other tertiary specialties are where KKR sees pricing power and volume growth, and Medicover India already operates across more than 80 such specialties.
We are pleased to invest in Medicover India and look forward to contributing to its next phase by investing behind its talent, technology, infrastructure and clinical capabilities, Akshay Tanna, Partner and Head of India Private Equity at KKR, said.
The deal caps a path that began in December 2024, when Medicover flagged an India listing for the unit as a strategic option. By June 2026, the parent confirmed it was in talks with KKR as an alternative to that planned IPO, per Medicover AB. The buyout closes the IPO question and hands the network a single owner with deep healthcare capital.
What does the deal mean for the sector?
For India’s hospital sector, the deal signals that global private equity now treats regional multi-specialty chains as premium assets. KKR has invested more than $20 Bn across healthcare globally since 2004, and its India roster already spans Max Healthcare, Healthium, and Gland Pharma, per KKR.
| KKR India Hospital Bet | Year | Note |
|---|---|---|
| Baby Memorial Hospital | 2024 | Controlling stake, Kerala-based chain |
| HealthCare Global (HCG) | 2025 | Up to 54% at Rs 445 per share, oncology chain |
| Medicover India | 2026 | 100% buyout, EUR 1.2 Bn, 24 hospitals |
What makes Medicover India different is scale at a single stroke: 24 hospitals and 4,800 beds bought outright, versus the staged stake purchases KKR used for HCG and Baby Memorial.
What’s Next
The transaction still needs Indian regulatory clearances, and both sides expect the deal to close in the fourth quarter of 2026, per Medicover AB. After close, KKR is likely to fund fresh capacity in cardiology and oncology, the specialties it has favoured across its portfolio. Will this EUR 1.2 Bn price tag pull more South India hospital chains into deal talks before the next financial year?
Frequently Asked Questions
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StartupFeed and its authors are not SEBI-registered investment advisors. The analysis above is based on publicly available information and should not be the sole basis for any investment decision. Please consult a SEBI-registered financial advisor before making investment decisions.
Have a tip? Write to us at editorial@startupfeed.in.
